
GLP-1 receptor agonists like liraglutide, semaglutide, and tirzepatide show promise in real-world obesity care, though weight loss is often less than in clinical trials. High discontinuation rates and lower dosing are common. While GI side effects persist, no major risks like pancreatitis are confirmed. Researchers call for more data on long-term outcomes and treatment gaps.
Like
Save
Share